- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02066350
Cardiovascular Risk Factors After Single Pancreas Transplantation (Diamant)
Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation
Patients accepted for the waiting list for single pancreas transplantation suffer from severe glucose instability with hyperglycemia due to diabetes type 1, but do not have significant diabetes-related complications. Pancreas transplantation restores normoglycemia in diabetes type 1 patients with unstable control of glycemia. Both hypo- and hyperglycemic events are abolished, and 70-80 % of the patients obtain satisfactory HbA1c levels (HbA1c 5.0-6.0 %) without the need of exogenous insulin. Endothelial dysfunction is considered as an early and potentially reversible stage in the atherosclerotic process. The endothelium is involved in homeostasis, leucocyte adhesion and vasomotor activity. Reduced endothelium-dependent vasodilation is associated with increments in cardiovascular risk factors, and endothelial dysfunction is a predictor for future cardiovascular disease. It has also been hypothesized that endothelial dysfunction may be involved in the impaired glycemic control by reducing the availability of glucose in peripheral muscles.Establishing normoglycemia by pancreas transplantation alone in previously diabetic type 1 patients has recently been shown to improve left ventricular ejection fraction, assessed by Doppler echocardiographic examination. In diabetic patients receiving a new pancreas it is possible to assess the effect of changing blood glucose excursions on cardiovascular risk factors, including endothelial function, without the use of antidiabetic drugs (exclude pleiotropic effects).
The primary objective of the present study is to assess if endothelial function (assessed by flow-mediated dilatation of arteria brachialis) is improved when hyperglycemia is reversed by single pancreas transplantation in patients with type 1 diabetes.
Secondary objectives are to investigate the changes in the following parameters by reversal of hyperglycemia by pancreas transplantation; Peripheral arterial tonometry, serum/plasma concentrations of endothelial dysfunction markers, blood pressure, lipid and lipoprotein concentrations.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Oslo, Norwegen, N-0424
- Oslo University Hospital, Rikshospitalet
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients with type 1 diabetes accepted for the waiting list for single pancreas transplantation
- Healthy volunteers (non-diabetic, non-transplanted)
- Over 18 years of age
- Signed informed consent
Exclusion Criteria:
- Non-functioning pancreas graft (defined as HbA1c ≥ 6.5 % with the need of insulin injections and fasting C-peptide concentration < 300 pmol/L).
- Active infection
- Active autoimmune disease other than diabetes
- Severe liver disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Single pancreas transplantation
This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation.
Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft.
A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Endothelial function
Zeitfenster: 1 year post-transplant
|
This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation.
Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft.
Flow-mediated dilatation (FMD) of large vessels (arteria brachialis) will be assessed by measuring vessel diameter by ultrasound and the FMD of micro vessels in the finger tip will be assessed by Endo-PAT (PAT=Peripheral Arterial Tonus) following reactive hyperperfusion induced by occlusion of the artery by a sphygmomanometer cuff.
|
1 year post-transplant
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Peripheral arterial tonometry
Zeitfenster: 1 year post-transplant
|
1 year post-transplant
|
|
Changes in cardiac performance
Zeitfenster: 1 year post-transplant
|
An echocardiographic examination will be performed to assess changes in cardiac performance, such as left ventricular ejection fraction
|
1 year post-transplant
|
Pulse wave velocity (arterial stiffness)
Zeitfenster: 1 year post-transplant
|
Pulse wave velocity, using a SphygmoCor device, measuring arterial stiffness will be performed in addition to pulse wave analysis evaluating the shape and amplitude of the aortic pulse wave.
|
1 year post-transplant
|
Heart rate variability
Zeitfenster: 1 year post-transplant
|
Heart rate variability will be assessed, using a Vagus device, analyzing short-term electrocardiogram recordings.
|
1 year post-transplant
|
Plasma concentrations of endothelial dysfunction markers
Zeitfenster: 1 year post-transplant
|
Fasting plasma samples (6 mL EDTA vacutainer) will be drawn for determination of relevant markers for endothelial dysfunction, such as von Willebrand factors (vWF) and vascular cell adhesion molecule-1 (VCAM-1).
|
1 year post-transplant
|
Blood pressure
Zeitfenster: 1 year post-transplant
|
Blood pressure will be measured seated after ten minutes rest by Dyna Map (Tuff.-Cuff,
CAS Medical system Inc.) and the mean of the lower two out of three measurements will be used.
|
1 year post-transplant
|
Lipid and lipoprotein concentrations
Zeitfenster: 1 year post-transplant
|
1 year post-transplant
|
|
Bone mineral density and body composition
Zeitfenster: 1 year post-transplant
|
Measurement of bone mineral density, using low dosage radiation (dual-energy X-ray absorptiometry (DEXA) scan) to assess the amount (grams) of mineral that are packed into a segment of bone.
In addition a body composition (visceral fat, metabolic measurement) will be determined using the DEXA scan.
|
1 year post-transplant
|
Glomerular filtration rate
Zeitfenster: 1 year post-transplant
|
Renal function, defined as glomerular filtration rate, will be evaluated by measuring iohexol clearance.
The concentration of iohexol (Omnipaque), a low dose non-ionic x-ray contrast medium of low osmolality, extensively used in clinical radiology and considered essentially free from side effects, will be measured 2 hours and 5 hours after iv injection of iohexol.
Like other iodine-containing contrast media, it is completely eliminated from the body by excretion in the urine, thus it is an ideal marker for kidney function.
It will be quantitated by chemical measurement based on the determination of iodine.
|
1 year post-transplant
|
Oral glucose tolerance test
Zeitfenster: 1 year post-transplant
|
Measurements of plasma glucose, C-peptide and serum insulin before, 30 and 120 minutes following an oral administration of 75 g glucose.
|
1 year post-transplant
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Trond G Jenssen, Professor, Oslo University Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2013/1062
- 2013047 (Andere Zuschuss-/Finanzierungsnummer: South-Eastern Norway Regional Health Authority)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Typ 1
-
Eledon PharmaceuticalsZurückgezogenSpröder Diabetes mellitus Typ 1Vereinigte Staaten
-
Shanghai Jiao Tong University School of MedicineRekrutierung
-
Hadassah Medical OrganizationUnbekanntUnkontrollierte Typ-1-Diabetiker
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AbgeschlossenDiabetes mellitus Typ 1 | T1DM | T1D | Neu aufgetretener Diabetes mellitus Typ 1Vereinigte Staaten, Australien
-
Shanghai Changzheng HospitalRekrutierungSpröder Diabetes mellitus Typ 1China
-
Capillary Biomedical, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, insulinabhängig, 1Australien
-
Spiden AGDCB Research AGRekrutierungDiabetes mellitus Typ 1 | Diabetes mellitus Typ 1 mit Hypoglykämie | Diabetes mellitus Typ 1 mit HyperglykämieSchweiz
-
Capillary Biomedical, Inc.BeendetDiabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Diabetes mellitus, insulinabhängig, 1 | IDDMÖsterreich
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnbekanntDiabetes mellitus Typ 1 mit Hyperglykämie | Diabetes mellitus Typ 1 mit HypoglykämiePolen
-
Poznan University of Medical SciencesUnbekanntDiabetes mellitus Typ 1 | Remission von Typ-1-Diabetes | Chronische Komplikationen von DiabetesPolen
Klinische Studien zur Single pancreas transplantation
-
Yale UniversityHarvard UniversityAbgeschlossenDiabetes Typ 1Vereinigte Staaten
-
Massachusetts General HospitalAbgeschlossen
-
Royan InstituteSmall Business Developing Center; Labafi Nejad Eye Research CenterAbgeschlossenMangel an limbalen StammzellenIran, Islamische Republik
-
Centro de Hematología y Medicina InternaAnmeldung auf Einladung
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNoch keine RekrutierungAutismus-Spektrum-Störung
-
University of MiamiAbgeschlossenKrebs | GehenVereinigte Staaten
-
Peking University People's HospitalAbgeschlossenFortgeschrittenes MDS ohne identischen GeschwisterspenderChina
-
International Peace Maternity and Child Health...Shanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaAbgeschlossenUnfruchtbarkeit | Primäre Ovarialinsuffizienz | Vorzeitige OvarialinsuffizienzChina
-
The Second Hospital of Nanjing Medical UniversitySIR RUN RUN hospital of Nanjing Medical UniversityNoch keine RekrutierungAufmerksamkeits-Defizit-Hyperaktivitäts-StörungChina
-
The Second Hospital of Nanjing Medical UniversityNoch keine Rekrutierung